JAK2 and myelofibrosis: Type1, but not type 2, is better than JAK2 mutations.26 Common mutations in MPL, W515L and W515K and MPL mutations, contribute to secondary myelofibrosis and AML.27 Two patients had the common variant,W515L and clinic state is stable.